FDA WARNING_LETTER - VapeKing ELiquid Engineering - June 18, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA Center for Tobacco Products issued a Warning Letter to VapeKing eLiquid Engineering after reviewing their website, vapeking.co.uk, which offers e-liquid products for sale in the U.S. These e-liquids are deemed tobacco products under section 201(rr) of the FD&C Act. The letter identifies two primary violations. First, the firm sold Vape King Apple 30ml e-liquid to a person younger than 18, violating 21 C.F.R. § 1140.14(b), rendering the product misbranded under section 903(a)(7)(B) of the FD&C Act. Second, several e-liquid products' labeling and/or advertising on the website failed to include the required nicotine warning statement ("WARNING: This product contains nicotine. Nicotine is an addictive chemical."), as mandated by 21 C.F.R. § 1143.3(a) and/or (b). This omission misbrands the products under section 903(a)(7)(B), and additionally under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act for false or misleading labeling/advertising. VapeKing must immediately correct these violations and submit a written response within 15 working days detailing corrective actions and a compliance plan. Failure to comply may result in further FDA actions, including civil money penalties, no-tobacco-sale orders, criminal prosecution, seizure, injunction, and refusal of admission for imports.
ID · 7e4d0293-2f4f-49f3-91af-9a6aad7bf122
Full citation text and observation details available on the Dashboard.